Investors looking to play the medical device trade, and find a solid dividend, should consider putting their money in Medtronic, said Shannon Saccocia, chief investment officer at SVB Private.
"This valuation is undemanding and looks quite attractive at this point along with the dividend yield," she told CNBC's " Halftime Report " on Monday.
So far this year, Medtronic shares have gained 6.4% after tumbling about 25% in 2022.
Shares also offer a dividend yield of roughly 3.3%, according to FactSet.
As Saccocia bought Medtronic, she sold shares of Merck , citing concerns about the pipeline for the company's cancer drug Keytruda.